drug_type
RELEVANT_DRUG
intervention_type
Cellular Therapy
drug_description
Lentiviral CAR T cells targeting GPRC5D; IV dose-escalated infusion; mediates MHC-independent killing of GPRC5D+ myeloma cells/plasma cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous/allogeneic T cells are lentivirally transduced to express a CAR specific for GPRC5D. Upon binding GPRC5D on malignant plasma cells, the CAR triggers MHC-independent T-cell activation, leading to cytotoxic killing via perforin/granzyme release and cytokine-mediated elimination of GPRC5D-positive myeloma cells.
drug_name
GPRC5D-directed CAR T cells
nct_id_drug_ref
NCT06849921